Pliant Therapeutics PLRX 深 沪
等待开盘 04-03 09:30:00 美东时间
1.35
+0.030
+2.27%
华盛通- 最 高1.38
- 今 开1.30
- 成交量 52.16万股
- 最 低 1.28
- 昨 收 1.32
- 总市值 8358.48万
- 52周最高 1.95
- 市盈率 静 --
- 换手率 0.84%
- 52周最低 1.09
- 委 比 -81.22%
- 总股本 6191.47万
- 历史最高 43.92
- 量 比 0.77
- 振 幅 7.58%
- 历史最低 1.09
- 每 手 1
- 风险率 0.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pliant Therapeutics Launches New $50 Million ATM Program
The latest announcement is out from Pliant Therapeutics ( ($PLRX) ). On March 3...
03-31 06:54
Pliant Therapeutics Presents Data From Phase 1 Trial Of PLN-101095 At AACR Annual Meeting 2026
Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of
03-18 21:03
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics announced the oral presentation of Phase 1 data for PLN-101095 at the AACR Annual Meeting in San Diego. The presentation, titled "First-in-human phase I study of PLN-101095," will be held on April 18, 2026, at 10:21 a.m. PT in Ballroom 6A. PLN-101095 is a dual αvβ8/αvβ1 integrin inhibitor designed to overcome immune checkpoint resistance by targeting TGF-β activation in the tumor microenvironment. The Phase 1 trial evaluates i...
03-18 13:00
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
Pliant Therapeutics GAAP EPS of -$0.38 in-line
Pliant Therapeutics press release (PLRX): Q4 GAAP EPS of -$0.38 in-line. As of December 31, 2025, the Company had cash, cash equivalents and short-term investments of $192.4 million which the Company ...
03-12 04:36
Pliant Therapeutics Q4 EPS $(0.38) Beats $(0.41) Estimate
Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.41) by 7.77 percent. This is a 53.66 percent increase over losses of $(0.82) per share
03-12 04:11
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
Lyell Immunopharma announced the closing of an additional $50 million equity private placement following the achievement of a clinical milestone for its CAR T-cell therapy rondecabtagene autoleucel. The company also appointed Smital Shah as Chief Financial and Business Officer.
03-09 12:00
Pliant Therapeutics Extends Stockholder Rights Agreement Expiration
The latest announcement is out from Pliant Therapeutics ( ($PLRX) ). On March 3...
03-04 08:49
